Title: Relative bioavailability of cefixime granules and dispersible tablets in human subjects
Abstract: Objective To compare the bioavailability of cefixime granules and dispersible tablets with marketed cefixime capsules in human subjects. Methods A reversed-phase high performance liquid chromatography was used for the determination of cefixime in serum after a single oral dose of 400 mg cefixime granules, dispersible tablets and marketed cefixime capsules in a cross-over design. Results the pharmacokinetic parameters of cefixime granules, dispersible tablets and marketed cefixime capsules were as follows: AUC0-1.were 29.45±10.67,29.12±10.38 and 29.53 ±10.71 μg·h·mL-1; AUC0-t were 28.38 ±9.94, 28.00±9.68 and 28.58 ±10.07 μg·h·mL-1; tmax were 3.83±0.37, 3.71±0.30 and 3.79±?0.34 ; Cmax were 4.79 ±?1.07, 4.84±1.04 and 4.77±10 μg·h·mL-1; t1/2were 2.35±0.42, 2.40 ±0.42 and 2.27 ±0.43 h, MRT0-T were 5.54±0.60, 5.50 ±62 and 5.55±0.66 h. F0-t were (99.77±8.74)% and (98.56±9.20)%; F0-8 were (100.17±9.11)% and (99.14 ±95)%, respectively. Conclusion The cefixime granules and dispersible tablets are bioequivalent with the marketed cefixime capsules.
Publication Year: 2004
Publication Date: 2004-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot